A 41.9-percentage-point placebo-adjusted EASI-75 response is not a marginal win — it is the kind of signal that forces a competitive reassessment in atopic dermatitis, a space already crowded with dupilumab, tralokinumab, and lebrikizumab. Zumilokibart’s mid-dose hit 65.9% EASI-75 at 16 weeks in the APEX Part B induction cohort, with only four injection days during that period versus nine for the current dupilumab standard. That dosing arithmetic matters more than the raw efficacy number, because every chronic inflammatory disease ultimately becomes a persistence and adherence problem.
The secondary endpoint stack is where the data get genuinely interesting. Mid-dose zumilokibart produced EASI-90 in 47.4% of patients and EASI-100 in 16.5%, against placebo rates of 9.3% and 3.4% respectively. The very low disease activity composite — requiring both EASI-90 and near-complete itch resolution — landed at 20.6%, a benchmark the press release correctly notes has not been demonstrated with any approved biologic in this indication. Conjunctivitis, the class liability that haunts IL-13 and IL-4/13 inhibitors, ran at 10.6% for the mid-dose, meaningfully lower than the high-dose arm’s 20.7% and below published dupilumab trial rates. The dose-selection logic for Phase 3 is therefore coherent: the mid-dose provides equivalent or superior efficacy to the high dose with a cleaner safety profile, not a compromise.
The strategic weight here extends beyond AD. Apogee has structured its APEX data to serve as the foundation for a multi-indication program, with Phase 2 trials in eosinophilic esophagitis planned for second-half 2026 and asthma for first-half 2027. The Blackstone Life Sciences financing collaboration announced simultaneously is designed to carry the program through commercialization — a signal that Apogee intends to develop zumilokibart independently rather than license it out at Phase 2 completion, which has been the exit strategy for most assets in this mechanistic class. That choice raises the execution risk but preserves the upside if Phase 3 replicates what APEX Part B and the 52-week Part A maintenance data collectively suggest.
The single endpoint to track as Phase 3 design details emerge is vLDA durability beyond induction. Part A demonstrated continued efficacy improvement through 52 weeks on every-three- and every-six-month dosing, but vLDA rates across that maintenance window have not been disclosed in granular form. If every-six-month dosing sustains the 20%-plus vLDA threshold seen at 16 weeks, the differentiation case against dupilumab’s label becomes structurally difficult for payers to ignore.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
2 Comments
Nektar Raises Cash to Fund Rezpegaldesleukin Phase 3 Trials Through 2028
2 months ago[…] JAK inhibitor experience. That stratified enrollment reflects a crowded treatment landscape where dupilumab and approved JAK inhibitors have already carved distinct patient segments, and where any new […]
Kymera Advances STAT6 Degrader KT-621 in Phase 2b Atopic Dermatitis, Asthma Trials
2 weeks ago[…] Dupilumab generated roughly $14 billion in 2025 sales by blocking IL-4/IL-13 signaling at the receptor level — and Kymera is now running two parallel Phase 2b trials betting that degrading STAT6, the transcription factor those cytokines activate, produces meaningfully deeper and broader suppression of Type 2 inflammation than any injectable biologic can reach. That is the actual hypothesis under test in BROADEN2 and BREADTH, and it is a more consequential clinical question than the trial designs alone suggest. […]
Comments are closed.